Aquestive Therapeutics Wins FDA Acceptance Of Anaphylm NDA Resubmission
Aquestive Therapeutics (AQST) announced the FDA accepted its resubmission for Anaphylm, a sublingual epinephrine film for severe allergic reactions. The FDA set a PDUFA goal date of March 16, 2027. The company addressed prior FDA concerns in the resubmission. If approved, Anaphylm could offer a needle-free treatment option. AQST stock closed at $4.61, up 1.30% in pre-market trading.
How this was made
The 30-second read
Why it matters
FDA acceptance of the resubmitted NDA as complete and Class 2 meaningfully advances the regulatory process and establishes a clear PDUFA goal date for review completion.
Market read
Traders can update probability-weighted expectations for an Anaphylm approval decision ahead of the first quarter 2027 window tied to the March 16, 2027 PDUFA goal date.
What to watch
The article does not disclose what specific issues were addressed from the prior Complete Response Letter, so traders may still discount the probability of approval until more detailed FDA feedback or clinical/regulatory updates emerge.
Background
Anaphylm (dibutepinephrine) is a polymer matrix-based, needle-free sublingual epinephrine oral film intended for rapid treatment of anaphylaxis.
Ticker impact
FDA accepted Aquestive’s Anaphylm NDA resubmission as a complete Class 2 response and set a PDUFA goal date of March 16, 2027.
Likely upward bias as traders price improved odds of eventual approval and a defined review schedule.
The article reports a concrete FDA procedural milestone (acceptance, Class 2 classification, and PDUFA goal date), which typically improves visibility versus a pending or incomplete filing.
Market effects
Highlights ongoing FDA review progress for epinephrine delivery alternatives, a niche within specialty pharma and allergy/emergency care.
Primarily US regulatory-driven sentiment for the biotech/specialty pharma complex.
Limited direct global spillover, but reinforces FDA’s continued scrutiny and process timelines for acute-care therapeutics.
Counterpoint
Acceptance does not equal approval; Class 2 still implies the FDA may require additional work or could ultimately reject the NDA.
Key entities
- companyAquestive Therapeutics
US-listed developer of Anaphylm, whose NDA resubmission was accepted by the FDA.
- regulatorFDA
Accepted the Anaphylm NDA resubmission as complete and set the PDUFA goal date.
- productAnaphylm (dibutepinephrine)
Sublingual oral film formulation of epinephrine for severe allergic reactions/anaphylaxis.
